Risk Stratification Flashcards

(31 cards)

1
Q

Step 1

A

Urgency of surgery? Proceed if it is an emergency.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Step 2

A

Unstable cardiac conditions defined by unstable coronary
syndromes, severe arrhythmias, decompensated heart failure
and symptomatic valvular disease; management of patients with
these conditions should be discussed by a multidisciplinary team
weighing the risks and benefits of delaying surgery to optimise
the patient.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Step 3

A

The risk of surgery low risk < 1%,

moderate risk 1–5%,

high risk > 5%.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Step 4

A

Functional capacity METS > 4 – Proceed.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Step 4

A

METS ≤ 4 consider surgical risk if it is low or moderate- proceed

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q
A

STEP 6: High-risk surgery with METS ≤ 4 used RCRI to evaluate risk
of MACE. Risk factors ≤ 2 consider biomarkers.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Step 7

A

STEP 7: RCRI score ≥ 3 noninvasive stress testing recommended.
Results with evidence of severe ischaemia, coronary
revascularisation should be considered.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Methods of preoperative cardiac risk assessment

A

RCRI- Most validated
NSQIP MICA
ACS NSQIP

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Advantage of rcri

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Advantage of NSQIP

A

Superior discrimination over rcri but may underestimate cardiac risk

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Disadvantages of NSQIP

A

No external validation
Underestimate risk

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Self reported functional capacity

A

MET

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q
A

did not predict perioperative cardiovascular
complications (adjusted odds ratio [aOR], 1.81; 95% CI,
0.94-3.46
METs were not inde-
pendently predictive of major perioperative cardiac compli-
cations.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Cardiac biomarkers

A

Brain natriuretic peptides (BNPs) and N-terminal frag-
ment of proBNP (NT-proBNP) are released from the
myocardium in response to various stimuli such as myocardial
stretch and ischemia.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q
A

We recommend measuring NT-proBNP or BNP
before noncardiac surgery to enhance perioperative
cardiac risk estimation in patients who are 65 years of
age or older, are 45-64 years of age with significant
cardiovascular disease, or have an RCRI score 1
(Strong Recommendation; Moderate-Quality Evi-
dence).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q
A

Values 300 ng/L for NT-proBNP and 92 mg/L
for BNP were identified as significant thresholds associated
with an increased risk of the primary outcome

17
Q
A

We recommend against performing preoperative
resting echocardiography to enhance perioperative
cardiac risk estimation (Strong Recommendation; Low-
Quality Evidence).

18
Q
A

The prognostic ca-
pabilities of an RCRI threshold 2 increased with the addi-
tion of an NT-proBNP threshold of 301 ng/L (ie, an RR of
1.4; 95% CI, 1.0-1.8 went to an RR of 3.7; 95% CI, 2.7-5.0;
P < 0.001); however, use of echocardiographic parameters in
addition did not result in a further increase in the RR

19
Q
A

We recommend against performing preoperative
CCTA to enhance perioperative cardiac risk estimation
(Strong Recommendation; Moderate-Quality
Evidence).

20
Q

VISION
CCTA study setup

A

This was a pro-
spective cohort study conducted at 12 centres in 8 countries that
evaluated the prognostic capabilities of preoperative CCTA to
enhance perioperative risk prediction beyond clinical data in
955 patients. The CCTA results were blinded unless significant
left main disease was identified, and patients had daily troponin
measurements for 3 days after surgery.22 The primary outcome
of cardiovascular death and nonfatal myocardial infarction
occurred in 74 patients (7.7%) within 30 days of surgery

21
Q
A

The study showed, compared with the RCRI alone, that
preoperative CCTA findings improved risk estimation (ie,extensive obstructive disease had an adjusted hazard ratio
[aHR], 3.76; 95% CI, 1.12-12.62) among patients who suffered the primary outcome, but also overestimated risk among patients who did not suffer the primary outcome. Although CCTA findings can appropriately improve risk estimation
among patients who will suffer the primary outcome, CCTA
findings are more than 5 times as likely to lead to an inappropriate overestimation of risk among patients who will not suffer a perioperative cardiovascular death or myocardial infarction.
The overall absolute net reclassification in a sample of 1000
patients is that CCTA will result in an inappropriate estimate of risk in 81 patients (on the basis of risk categories of < 5%, 5%-
15%, and > 15% for the primary outcome).

22
Q
A

We recommend against performing preoperative ex-
ercise stress testing to enhance perioperative cardiac
risk estimation (Strong Recommendation; Low-
Quality Evidence).

23
Q
A

We recommend against performing preoperative
CPET to enhance perioperative cardiac risk estima-
tion (Strong Recommendation; Low-Quality
Evidence).

24
Q
A
  1. We recommend against performing preoperative
    pharmacological stress echocardiography to enhance
    perioperative cardiac risk estimation (Strong Recom-
    mendation; Low-Quality Evidence).
  2. We recommend against performing preoperative
    pharmacological stress radionuclide imaging to
    enhance perioperative cardiac risk estimation (Strong
    Recommendation; Moderate-Quality Evidence).
    Values and preferences. The panel believed that
    the cost and potential delays associated with these stress
    tests should be taken into account because of the
    absence of evidence of an overall absolute net
    improvement in risk reclassification.
25
Pulmonary Embolism Prevention (PEP) trial
showed that ASA prevents venous thromboembolism (HR, 0.64; 95% CI, 0.50-0.81) in patients who undergo hip fracture surgery.54 In PEP, ASA was associated with an increased risk of myocardial infarction (HR, 1.33; 95% CI, 1.00-1.78); however, there was no systematic monitoring of cardiac biomarkers after surgery, and there were only 184 myocardial infarctions.
26
The Perioperative Ischemic Evaluation-2 (POISE-2) trial
large RCT of 10,010 patients who underwent a wide spectrum of in-hospital noncardiac surgeries.55 Patients who underwent a carotid endarterectomy, had received a bare- metal stent in the 6 weeks before surgery, or had received a drug-eluting stent in the 12 months before surgery were excluded from the trial. Patients had systematic monitoring of cardiac biomarkers or enzymes for the first 3 days after surgery. POISE-2 included 5628 patients who were not previously taking ASA and 4382 patients who were taking ASA chronically but had stopped taking it a minimum of 3 days (median of 7 days) before surgery
27
POISE-2 showed no effect of ASA on myocardial infarction and cardiac or all-cause mortality. POISE-2, similar to PEP, showed perioperative ASA increased the risk of major bleeding.
28
. We recommend against initiation of ASA for the prevention of perioperative cardiac events (Strong Recommendation; High-Quality Evidence). 15. We recommend against the continuation of ASA to prevent perioperative cardiac events, except in patients with a recent coronary artery stent and patients who undergo carotid endarterectomy (Strong Recommen- dation; High-Quality Evidence
29
We recommend against b-blocker initiation within 24 hours before noncardiac surgery (Strong Recommen- dation; High-Quality Evidence) Among patients taking a b-blocker chronically, we suggest to continue the b-blocker during the periop- erative period (Conditional Recommendation; Low-Quality Evidence
30
We recommend against preoperative initiation of an a2-agonist for the prevention of perioperative cardiovascular events (Strong Recommendation; High-Quality Evidence
31
Evidence for alpha 2